Skip Nav Destination
Issues
1 February 2011
-
Cover Image
Cover Image
Multivariate analysis and high-content imaging allow the detailed investigation of treatment effects at the cellular level, yet the reproducibility of such assessments has not been thoroughly investigated. A model calibrated at each experiment accounts for variation in experimental conditions and allows for the reproducible assessment of phenotype induced by cell cycle modulators. An extensive survey of cell cycle inhibitors highlights the prevalence of phenotypic variability in response to agents within a mechanistic class and the occurrence of concentration-dependent changes in phenotype. For details, see the article by Sutherland and colleagues on page 242. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Highlights
Therapeutic Discovery
Preclinical Development
Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
Noriaki Sunaga; David S. Shames; Luc Girard; Michael Peyton; Jill E. Larsen; Hisao Imai; Junichi Soh; Mitsuo Sato; Noriko Yanagitani; Kyoichi Kaira; Yang Xie; Adi F. Gazdar; Masatomo Mori; John D. Minna
Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
Christian Thomas; Amina Zoubeidi; Hidetoshi Kuruma; Ladan Fazli; Francois Lamoureux; Eliana Beraldi; Brett P. Monia; A. Robert MacLeod; Joachim W. Thüroff; Martin E. Gleave
Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Timothy A. Yap; Mike I. Walton; Lisa-Jane K. Hunter; Melanie Valenti; Alexis de Haven Brandon; Paul D. Eve; Ruth Ruddle; Simon P. Heaton; Alan Henley; Lisa Pickard; Gowri Vijayaraghavan; John J. Caldwell; Neil T. Thompson; Wynne Aherne; Florence I. Raynaud; Suzanne A. Eccles; Paul Workman; Ian Collins; Michelle D. Garrett
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.